NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
This NIH/NHLBI R33 supports investigator-initiated Phase I clinical trials for therapeutics or diagnostics for heart, lung, blood, and sleep disorders; a clinical trial is required and applicants m…
- Deadline
- Jan 7, 2027
- Posted
- Dec 5, 2024
- Award amount
- Up to $1,515,000
- Focus areas
- Health
Don’t miss this deadline
We’ll email you before Jan 7, 2027 so you have time to apply.
In plain English
This NIH/NHLBI R33 supports investigator-initiated Phase I clinical trials for therapeutics or diagnostics for heart, lung, blood, and sleep disorders; a clinical trial is required and applicants must be ready to start the trial early. Eligible applicants include universities, research institutions, and tribal and community organizations; foreign organizations are not eligible to apply, though non-U.S. components of U.S. organizations are. The maximum award is about $1.5 million. It requires clinical-trial readiness.
AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.
Who can apply
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
About this grant
The objective of this funding opportunity is to support investigator-initiated, phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multisite. Applicants applying for funding under this NOFO should be ready to initiate the clinical trial within the first quarter of the project period. Discussion, submission, and attainment of applicable regulatory (FDA, DSMB, IRB) approvals, and establishment of drug (and placebo, if applicable) supplies, and any necessary third-party agreements should be established by the time of award. If time and support for these and other pre-clinical and/or trial readiness activities are desired, applicants should consider the companion NOFO which utilizes an R61/R33 phased approach.
Let AI draft your application
Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.
Application Kit — $49 one-time
Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.
Get the Application Kit →Related grants
Other open grants funding Health — soonest deadline first.
Cooperative Agreement for In Vivo High-Resolution Imaging for Inner Ear Visualization (U01 Clinical Trial Required)
National Institutes of Health · Up to $500K · Due Oct 1, 2026
In Vivo High-Resolution Imaging for Inner Ear Visualization (R01 Clinical Trial optional)
National Institutes of Health · Up to $500K · Due Oct 1, 2026
Alcohol Health Services Research (R01 Clinical Trial Optional)
National Institutes of Health · Up to $500K · Due in 17 days
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)
National Institutes of Health · Up to $500K · Due in 17 days
Advancing Research on the Application of Digital Health Technology to the Management of Type 2 Diabetes (R01- Clinical Trail Required)
National Institutes of Health · Amount varies · Due Oct 6, 2026
Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Clinical Centers (U01 Clinical Trial Required)
National Institutes of Health · Up to $1M · Due Oct 9, 2026
Also listed under National Institutes of Health and Health Grants.
Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.